At the 2023 American Society of Clinical Oncology Annual Meeting, Dr. Slamon presented results from the NATALEE trial, showing that Kisqali plus an aromatase inhibitor after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer, reduced recurrence risk by 25% compared to an aromatase inhibitor alone.
Listen to the podcast to hear Dr. Slamon explain:

why he thought Kisqali could benefit people with early-stage breast cancer

the side effects Kisqali can cause

what the results mean for people diagnosed with early-stage, hormone receptor-positive disease